Journal of Obesity & Metabolic Syndrome

Search

Article

Korean J Obes 2005; 14(2): 94-100

Published online April 1, 2005

Copyright © Korean Society for the Study of Obesity.

Effects of Voglibose and Glimepiride on Body weight in Patients with Type 2 Diabetes.

Sun Hye Jung, Dae Jung Kim, Kwan-Woo Lee, Bom Taeck Kim¹, Sung Soo Kim², Eun Sook Kim³, Ji Oh Mok⁴, Chul Woo Ahn5, Hyun Dae Yoon6, Sangyeoup Lee7, Chang Beom Lee8, Seong Bin Hong9

Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea,
Department of Family practice and Community health, Ajou University School of Medicine, Suwon, Korea¹;
Department of Family Medicine, Chungnam National University Hospital, Daejeon, Korea²;
Department of Internal Medicine, Ulsan University College of Medicine, Seoul, Korea³;
Department of Internal Medicine, College of Medicine, Soonchunhyang University, Korea⁴;
Division of Endocrinology and Metabolism;
Department of Internal Medicine, Yonsei University College of Medicine, Seoul Korea5;
Department of Internal Medicine, Catholic University of Daegu, School of Medicine, Daegu, Korea6;
Center of Obesity, Nutrition and Meabolism, Pusan National University Hospital, Pusan, Korea7;
Department of Internal Medicine, Hanyang University Guri Hospital, Korea8;
Department of Internal Medicine, College of Medicine Inha University, Incheon, Korea9

Abstract

Background: Obesity is a major risk factor for type 2 diabetes. Improvement in glycemic control using insulin, sulfonylurea and meglitinide is often accompanied by weight gain. But metformin and a-glucosidase inhibitor have a positive effect(decrease) on weight. In this study, we compared the effect of voglibose, glimepiride, and diet alone on body weight and glycemic control after a period of 12 weeks.
Method: The patients with type 2 diabetes were randomly assigned to one of the following three treatment groups : Patients treated for 12 weeks with voglibose, those treated with glimepiride and those with diet alone. Anthropometric parameters and metabolic parameters were measured at the initial stage and after 12 weeks. The study consisted of 448 patients with type 2 diabetes. There were 223 patients in the voglibose group, 176 in the glimepiride group, and 49 in the diet alone group.
Results: The patients treated with voglibose and diet alone showed higher decreased body weight compared with glimepirice group (voglibose vs glimepiride, P=0.001; diet vs glimepiride, P=0.016). In contrast, glimepiride group showed more decreased HbA1C compared with voglibose and diet alone groups (glimepiride vs voglibose, P=0.001; glimepiride vs diet, P=0.004).
Conclusions: Voglibose showed more effective on body weight reduction despite the relatively weak glycemic control compared with glimepiride.

Keywords: voglibose, glimepiride, body weight, type 2 diabetes

Share this article on :

Related articles in Jomes